Previous studies have shown that several protein kinase inhibitors are time-dependent inhibitors of cytochrome P450 (CYP) 3A. We screened 14 kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A. Amodiaquine N-deethylation and midazolam 19-hydroxylation were used as marker reactions for CYP2C8 and CYP3A activity, respectively. A screening, IC 50 shift, and mechanismbased inhibition were assessed with human liver microsomes. In the screening, bosutinib isomer 1, crizotinib, dasatinib, erlotinib, gefitinib, lestaurtinib, nilotinib, pazopanib, saracatinib, sorafenib, and sunitinib exhibited an increased inhibition of CYP3A after a 30-min preincubation with NADPH, as compared with no preincubation. Axitinib and vandetanib tested negative for time-dependent inhibition of CYP3A and CYP2C8, and bosutinib was the only inhibitor causing timedependent inhibition of CYP2C8. The inhibitory mechanism by bosutinib was consistent with weak mechanism-based inhibition, and its inactivation variables, inhibitor concentration that supports half-maximal rate of inactivation (K I ) and maximal inactivation rate (k inact ), were 54.8 mM and 0.018 1/min. As several of the tested inhibitors were reported to cause mechanism-based inactivation of CYP3A4 during the progress of this work, detailed experiments with these were not completed. However, lestaurtinib and saracatinib were identified as mechanism-based inhibitors of CYP3A. The K I and k inact of lestaurtinib and saracatinib were 30.7 mM and 0.040 1/min, and 12.6 mM and 0.096 1/min, respectively. Inhibition of CYP2C8 by bosutinib was predicted to have no clinical relevance, whereas therapeutic lestaurtinib and saracatinib concentrations were predicted to increase the plasma exposure to CYP3A-dependent substrates by ‡2.7-fold. The liability of kinase inhibitors to affect CYP enzymes by time-dependent inhibition may have long-lasting consequences and result in clinically relevant drug-drug interactions.
Introduction
In recent years, several therapeutic protein kinase inhibitors have been approved for cancer treatment, and numerous are under investigation. These drugs target specific mutated or overexpressed protein kinase receptors, which are associated with cancer initiation or progression. Because cancer patients are typically treated with many medications concurrently, a careful assessment of the drug-drug interaction potential of these novel cancer drugs is important.
Recently, several protein kinase inhibitors such as dasatinib, erlotinib, gefitinib, imatinib, and lapatinib have been demonstrated to affect the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 by mechanism-based inhibition in vitro (Li et al., 2009 (Li et al., , 2010 Dong et al., 2011; Filppula et al., 2012; Kenny et al., 2012) . Unlike reversible inhibition, mechanism-based inhibition leads to a permanent inactivation of the enzyme, so that enzyme activity can be regained only by synthesis of new enzyme. In vitro, this inhibition type is characterized by a concentration, NADPH, and time dependence, because the inhibitor is first metabolized to an intermediate, which then binds covalently to the metabolizing enzyme (Silverman, 1995; VandenBrink and Isoherranen, 2010) . In the clinics, these characteristics can manifest in a slow onset and a long-lasting inhibition, making a careful assessment of this inhibition mechanism and its clinical consequences particularly important. For instance, 400 mg imatinib daily has increased the area under the plasma concentration-time curve (AUC) of the CYP3A4 substrate simvastatin on average by 3.5-fold, with individual changes for the subjects ranging from no increase to .10-fold increase in AUC (O'Brien et al., 2003) . This interaction cannot be explained based on published values for direct CYP3A4 inhibition by imatinib (Filppula et al., 2012) .
Besides altering the pharmacokinetics of concomitantly administered drugs, mechanism-based inhibitors may also affect their own metabolism by time-dependent autoinhibition. As most protein kinase inhibitors are reported to undergo metabolism by CYP3A4 Scheffler et al., 2011; Pajares et al., 2012) , variability in the expression of this enzyme together with a possible autoinhibition may be one explanation for the large interindividual variability (25-80%) observed in the clearance of protein kinase inhibitors (Sparreboom and Verweij, 2009; Di Gion et al., 2011; Pajares et al., 2012) . Moreover, autoinhibition of CYP3A4 could increase the relative importance of other enzymes in the metabolism of these drugs.
For imatinib, autoinhibition of CYP3A4 has been suggested to increase the role of CYP2C8 in its pharmacokinetics during long-term medication (Filppula et al., 2013) . Also, other protein kinase inhibitors such as erlotinib, nilotinib, pazopanib, and sunitinib are metabolized by CYP2C8 to various degrees (http://www.accessdata.fda.gov/ drugsatfda_docs/nda/2007/022068s000_ClinPharmR.pdf, http://www. accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_ S000_Sutent_BioPharmR.pdf) (Rakhit et al., 2008) . During recent years, CYP2C8 has gradually gained increased attention as clinically relevant CYP2C8 substrates and inhibitors have been identified (Backman et al., 2002; Niemi et al., 2003a; Niemi et al., 2003b; Jaakkola et al., 2005; Niemi et al., 2006; Tornio et al., 2007; Karonen et al., 2010) , functional CYP2C8 single-nucleotide polymorphisms have been characterized, and its crystal structure has been resolved (Dai et al., 2001; Bahadur et al., 2002; Schoch et al., 2004) . These studies have shown that the active sites of CYP2C8 and CYP3A4 are similar in size, but differ in shape, which most likely explains why CYP2C8 and CYP3A4 often have common substrates but yield different metabolite profiles (Totah and Rettie, 2005; Aquilante et al., 2013) .
In the present study, we first screened 14 kinase inhibitors for their potential to inhibit CYP2C8 and CYP3A by NADPH-and timedependent inhibition. Inhibitors that caused an increased inhibition following preincubation with NADPH, as compared with no preincubation, and which had not previously been identified as time-dependent inhibitors, were further investigated in IC 50 and mechanism-based inhibition experiments. We then carried out static predictions to estimate the potential clinical relevance of our in vitro findings.
Materials and Methods
Chemicals and Microsomes. Human liver microsomes (HLM) were obtained from BD Biosciences (Woburn, MA). Axitinib, bosutinib, bosutinib isomer 1 (4-[(3,5-dichloro-4-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile), erlotinib hydrochloride, gefitinib, lestaurtinib, nilotinib, pazopanib, saracatinib, sorafenib, sunitinib, and vandetanib were purchased from LC Laboratories (Woburn, MA). Crizotinib, dasatinib, and montelukast were from Sequoia Research Products (Pangbourne, U.K.), and amodiaquine dihydrochloride dihydrate, ammonium formate, and b-NADPH from Sigma-Aldrich (St. Louis, MO). N-desethylamodiaquine hydrochloride and N-desethylamodiaquine-d5 were purchased from Toronto Research Chemicals (North York, ON, Canada), ketoconazole from Janssen Biotech (Olen, Belgium), midazolam from Hoffmann-La Roche (Basel, Switzerland), and 19-hydroxymidazolam from SPI-Bio (Montigny Le Bretonneux, France). Triazolam was obtained from Upjohn (Kalamazoo, MI), and acetonitrile and methanol from Rathburn Chemicals (Walkerburn, Scotland). Other chemicals were from Merck (Darmstadt, Germany).
Incubation Conditions. Amodiaquine N-deethylation and midazolam 19-hydroxylation were used as marker reactions for CYP2C8 and CYP3A activity, respectively. The incubations contained HLM (0.1 mg/ml protein, if not otherwise indicated) in 0.1 M sodium phosphate buffer (pH 7.4). Amodiaquine and midazolam concentrations were 2 or 10 mM depending on experiment, as described in detail below. To evaluate the inhibitory effects of axitinib, bosutinib, bosutinib isomer 1, crizotinib, dasatinib, erlotinib, gefitinib, lestaurtinib, pazopanib, nilotinib, saracatinib, sorafenib, sunitinib, and vandetanib (Supplemental Fig. 1 ) on CYP2C8 and CYP3A activities, inhibitor concentrations between 0.01 and 500 mM (depending on inhibitor tested) were added to the incubation mixtures.
In direct inhibition incubations, inhibitor or solvent control and substrate were premixed with microsomes and buffer for 3 min before addition of 1.0 mM NADPH, which initiated the reactions. In time-dependent inhibition incubations, the inhibitor or buffer control was preincubated with HLM for up to 30 min with NADPH, followed by addition of substrate to initiate the reaction. The final incubations were performed in a shaking water bath (37°C) for 2 min. Reactions were stopped by moving 100 ml sample to 300 ml mobile phase B solution containing N-desethylamodiaquine-d5 and triazolam as internal standards. Samples were thereafter handled as previously described (Filppula et al., 2012) .
Amodiaquine, ketoconazole, midazolam, and montelukast were dissolved in methanol, bosutinib, bosutinib isomer 1, crizotinib, lestaurtinib, saracatinib, and vandetanib in ethanol, and all other inhibitor compounds in dimethylsulfoxide. In the preliminary screening and IC 50 experiments, the final solvent concentration in all incubations (including controls) with bosutinib, bosutinib isomer 1, crizotinib, lestaurtinib, saracatinib, and vandetanib was 1%, whereas in all incubations (including controls) for the other inhibitors it was 0.2%. In mechanism-based experiments with bosutinib, lestaurtinib, and saracatinib, the solvent concentration was #1%. Due to solubility limitations, bosutinib concentrations .150 mM and vandetanib concentrations .180 mM could not be tested. Incubations were performed in duplicates (controls in triplicates), and the incubation time was within the linear range for the rates of metabolite formation.
Measurement of Drug Concentrations. Sample handling and determination of N-desethylamodiaquine and 19-hydroxymidazolam concentrations using an Agilent 1100 series high-performance liquid chromatography system (Agilent Technologies, Waldbronn, Germany) coupled to a SCIEX API 2000 tandem mass spectrometer (MDS Sciex, Concord, ON, Canada) were conducted, as previously described (Filppula et al., 2012) . The lower limit of quantification was 0.001 mM for N-desethylamodiaquine and 0.002 mM for 19-hydroxymidazolam. The interday coefficient of variation for N-desethylamodiaquine was 16% at 0.001 mM, 9.4% at 0.01 mM, and 6.7% at 0.1 mM, and for 19-hydroxymidazolam it was 15% at 0.002 mM, 11% at 0.02 mM, and 7.4% at 0.2 mM. Due to technical issues, samples from the experiment with competitive inhibitors and part of the mechanism-based experiment for bosutinib were analyzed by use of an API 3000 liquid chromatography tandem mass spectrometry system (MDS Sciex) using the same method as with the API 2000 system. With the API 3000 system, the interday coefficient of variation for N-desethylamodiaquine was 13% at 0.001 mM, 11% at 0.01 mM, and 2.0% at 0.1 mM, and for 1'-hydroxymidazolam it was 13% at 0.002 mM, 11% at 0.02 mM, and 3.4% at 0.2 mM.
Screening and IC 50 -Shift Experiments. Inhibitor concentrations causing approximately 50% and 20-30% direct inhibition of CYP2C8 and CYP3A activity or buffer control were simultaneously incubated with 2 mM substrate (direct inhibition) or first preincubated with NADPH for 30 min, after which 2 mM substrate was added to the mixture (metabolism-dependent inhibition). Compounds inhibiting CYP2C8 and/or CYP3A activity in a time-dependent manner, and which had not previously been identified as time-dependent inhibitors, were further investigated in IC 50 -shift experiments. In addition, as no IC 50 values for CYP2C8 and CYP3A inhibition by axitinib had been published at the time of the study, we also conducted IC 50 incubations for axitinib. The IC 50 experiments were carried out similarly as the screening, but inhibitor concentrations tested ranged from 0.01 to 500 mM, causing enzyme inhibition from 0 to nearly 100%. In the screening, bosutinib isomer 1 was also tested, but it was not included in further experiments as it is not under investigation as a therapeutic drug.
Mechanism-Based Inhibition and Follow-Up Experiments. Inhibitors that caused a decrease of $1.5-fold for IC 50 with a 30-min preincubation, as compared with no preincubation (Grimm et al., 2009) , were selected for characterization of time-dependent inhibition. Briefly, various inhibitor concentrations were preincubated with 0.5 mg/ml HLM and NADPH for up to 30 min. At determined time points, an aliquot of 15 ml preincubation mixture was moved to another tube containing NADPH and 10 mM amodiaquine or midazolam in buffer in a final incubation volume of 300 ml. Accordingly, the protein and inhibitor concentrations had been diluted 20-fold, and a substrate concentration higher than its Michaelis-Menten constant was used to minimize direct inhibition by the inhibitors.
To determine the effect of a competitive inhibitor on the time-dependent inactivation of CYP2C8 by bosutinib and of CYP3A by lestaurtinib and saracatinib, preincubation mixtures were prepared as above. However, for bosutinib, preincubations were carried out with or without montelukast (0.5 and 5 mM) as CYP2C8 inhibitor, both in the absence (control) and presence of bosutinib (150 mM). Similarly, for lestaurtinib and saracatinib, preincubation tubes contained ketoconazole (0.1 and 1 mM) as CYP3A inhibitor, without (control) or with lestaurtinib (30 mM) or saracatinib (10 mM). Mixtures were then preincubated for 30 min; aliquots were transferred to incubation tubes (20-fold dilution), and the residual amodiaquine deethylation (for bosutinib) or midazolam 19-hydroxylation activity (for lestaurtinib and saracatinib) was measured, as explained above.
To evaluate the effect of dialysis on the inhibitory effects of bosutinib, lestaurtinib, and saracatinib, HLM (0.5 mg/ml) were preincubated with or dmd.aspetjournals.org without inhibitor (150 mM bosutinib, 200 mM lestaurtinib, or 64 mM saracatinib) and NADPH for 30 min. The preincubation mixtures were then immediately dialyzed against 0.1 M sodium phosphate buffer (pH 7.4) three times for 2 h in a volume of 2 l at 4°C, and followed by a 20-fold dilution and measurement of CYP2C8 or CYP3A marker reactions, as explained above.
Data Analysis. IC 50 values were determined by nonlinear regression analysis using SigmaPlot (version 11.0; Systat Software, San Jose, CA). For estimation of metabolism-dependent inactivation constants, preincubation time-dependent loss of CYP2C8 or CYP3A activity in the absence of the inhibitor was accounted for by adjusting the observed metabolism rate with reference to the respective control (vehicle) incubation at each preincubation time. The initial rate constant of CYP enzyme inactivation (K obs ) by each inhibitor concentration was determined by linear regression analysis of the natural logarithm of the initial linear portion of the plotted percentage of activity remaining versus preincubation time (Kitz and Wilson, 1962) . Thereafter, the K obs values were used to determine the maximum inactivation rate (k inact ) and the inhibitor concentration needed to cause half of k inact [inhibitor concentration that supports half-maximal rate of inactivation (K I )]. Preliminary estimates of K I and k inact were obtained from a double-reciprocal plot of K obs (y-axis) versus inhibitor concentration [I] (x-axis) (Kitz and Wilson, 1962) . Final K I and k inact values were then estimated by nonlinear regression using the following equation: (Kitz and Wilson, 1962; Jones et al., 1999) .
Drug-Drug Interaction Predictions. Obtained K I , k inact , and direct IC 50 values were used for predictions of the potential clinical impact of the inhibition. For substrates that are metabolized in both intestine and liver, the following equation can be used to simultaneously evaluate the potential clinical impact of both competitive (direct) and mechanism-based inhibition (Fahmi et al., 2008) :
where AUC po,i and AUC po are the areas under the concentration-time curve of the substrate in the presence and absence of an inhibitor, respectively, fm P450i expresses the fraction of the substrate dose cleared by a specific P450 enzyme, and F G describes the intestinal bioavailability of the substrate. A and C are mechanism-based inhibition components in the liver and intestine, respectively, and B and D are competitive inhibition components in the liver and intestine, respectively:
k deg is the rate constant of hepatic or intestinal P450 degradation in the absence of the inhibitor. In our predictions, a half-life of 22 h (k deg corresponds to 0.00053 1/min) was used for CYP2C8 (Backman et al., 2009 ). The CYP3A inhibition observed in our incubations was assumed to be completely due to inhibition of CYP3A4, and 36 and 23 h were used as the CYP3A4 half-life in the liver and intestine, respectively (corresponding to k deg values of 0.00032 and 0.00050 1/min, respectively) (Fromm et al., 1996; Greenblatt et al., 2003; Rowland Yeo et al., 2011) . As no direct reversible inhibition constant (K i ) values were determined in the present study, we used direct IC 50 /2 instead. Predictions were carried out for clinically relevant unbound plasma concentrations of the inhibitors. Intestinal inhibitor concentrations were calculated assuming no binding of the inhibitor to enterocytic proteins (f u,gut = 1).
First, predictions considering direct and mechanism-based inhibition of hepatic CYP2C8 and CYP3A4 by bosutinib, lestaurtinib, and saracatinib were carried out for substrates with fraction metabolized by CYP2C8 or CYP3A4 varying from 0.5 to 1. These predictions were related to steady state unbound peak concentration (C max,u ), and unbound hepatic inlet peak (C max,u,hep,inlet ) concentration of the inhibitors in plasma during standard dosing regimen (Supplemental Table 1 ). The unbound hepatic inlet peak concentrations were calculated according to (Ito et al., 1998) :
where f u represents the plasma unbound fraction, k a is the absorption rate constant, f a is the fraction absorbed, and Q h expresses the hepatic blood flow (20.7 ml/min/kg) (Houston and Galetin, 2008) . f a was assumed to be 0.8 (Kenny et al., 2012) . f u , k a , and dose for each inhibitor are described in Supplemental Tables 1 and 2 . In addition, predictions based on direct inhibition of CYP2C8 and CYP3A4 by axitinib and of CYP2C8 by gefitinib were conducted using the described equations (Supplemental Tables 1 and 2) .
Then, the reduction in intestinal CYP3A4 activity after administration of bosutinib, lestaurtinib, and saracatinib was calculated as follows:
Remaining intestinal CYP3A4 activity ¼ C Â D using intestinal inhibitor concentrations [I] G . These concentrations were estimated using the following equation (Rostami-Hodjegan and Tucker, 2004) :
where Q ent represents the enterocytic blood flow (248 ml/min) (Supplemental Table 2 ).
Finally, CYP3A4 inhibitor interactions with midazolam were predicted with the assumption that fm CYP3A4 and F G of midazolam are 0.94 and 0.51 (Galetin et al., 2006; Gertz et al., 2010) , respectively.
Results
Screening of Time-Dependent Inhibition of CYP2C8 in HLM Incubations. In the screening, all inhibitors tested caused direct CYP2C8 inhibition at different concentrations. However, axitinib, nilotinib, and sorafenib were identified as potent direct inhibitors of CYP2C8, causing a ;50% decrease in CYP2C8 activity at low concentrations (0.15, 0.2, and 0.7 mM, respectively) ( Fig. 1, Supplemental  Fig. 2, Supplemental Table 3 ). At the concentrations tested, bosutinib, gefitinib, and saracatinib caused a moderate or small time-and NADPHdependent increase in inhibition of CYP2C8 activity (Fig. 1 , Supplemental Fig. 2 ) and were further tested in IC 50 experiments. Compared with no preincubation, inhibition of CYP2C8 decreased after a 30-min preincubation with NADPH in incubations with axitinib, dasatinib, erlotinib, lestaurtinib, nilotinib, pazopanib, sorafenib, and sunitinib, suggesting that these inhibitors had been extensively metabolized during the preincubation to metabolites that did not affect CYP2C8 activity. Unlike in incubations with bosutinib, preincubation of bosutinib isomer 1 with NADPH did not increase CYP2C8 inhibition. In addition, preincubation of crizotinib with NADPH did not alter its inhibition of CYP2C8, as compared with direct inhibition.
Screening of Time-Dependent Inhibition of CYP3A in HLM Incubations. As previously recognized in the literature (Supplemental Table 4 ), the inhibition of CYP3A activity by crizotinib, dasatinib, erlotinib, gefitinib, nilotinib, pazopanib, sorafenib, and sunitinib increased after preincubation for 30 min with NADPH (Fig. 1 , Supplemental Fig. 2) . As new findings, lestaurtinib and saracatinib also affected CYP3A in this way, and they were therefore further tested in IC 50 experiments. In addition, unlike bosutinib, preincubation of bosutinib isomer 1 with NADPH increased the inhibition of CYP3A. With the exception of erlotinib, gefitinib, and vandetanib, all inhibitors tested affected CYP3A by direct inhibition. Vandetanib (180 mM) did not inhibit CYP3A at all, whereas erlotinib and gefitinib markedly stimulated the formation of 19-hydroxymidazolam in direct inhibition experiments (Fig. 1, Supplemental Fig. 2) .
IC 50 Experiments. Preincubation of bosutinib with NADPH resulted in a 2.6-fold decrease in its IC 50 value for CYP2C8 inhibition to 16.9 mM (Fig. 2) , and it was therefore further tested in mechanism-based experiments. In contrast to preliminary findings, gefitinib and saracatinib did not increase the inhibition of CYP2C8 following preincubation. Following preincubation, the IC 50 value for CYP3A inhibition by lestaurtinib decreased 2.2-fold to 2.1 mM. Likewise, after preincubation, the IC 50 of saracatinib was markedly decreased, by 26-fold to 1.8 mM.
Mechanism-Based Inhibition of CYP2C8 and CYP3A. The inhibition of CYP2C8 activity by bosutinib and of CYP3A activity by lestaurtinib and saracatinib was concentration-, NADPH-, and preincubation time-dependent (Fig. 3) . With the nonlinear regression method, apparent inactivation variables K I and k inact for CYP2C8 by bosutinib were estimated to 54.8 mM and 0.018 1/min. For lestaurtinib, the K I and k inact for CYP3A inhibition were 30.7 mM and 0.040 1/min, and for saracatinib 12.6 mM and 0.096 1/min. The k inact values imply that approximately 2% of CYP2C8 and 4 and 10% of CYP3A are inactivated each minute when saturating concentrations of bosutinib, lestaurtinib, and saracatinib, respectively, are incubated with HLM.
In subsequent experiments, ketoconazole reduced the lestaurtiniband saracatinib-induced inactivation of CYP3A, in a concentrationdependent manner (Table 1) . Montelukast reduced the inactivation of CYP2C8 by bosutinib only slightly. However, dialysis of preincubated HLM-bosutinib mixture for 3 ☓ 2 h at 4°C did not abolish the inhibitory effect of bosutinib on amodiaquine deethylation (Table 2) . Similarly, dialysis of preincubated HLM-lestaurtinib and HLMsaracatinib solution did not abolish the inhibitory effects of lestaurtinib and saracatinib on midazolam 19-hydroxylation.
Prediction of In Vivo Drug Interactions Due to Inhibition of CYP2C8 or CYP3A. The predicted fold increase in the AUC of a victim drug with different fractions metabolized by CYP2C8 or CYP3A4 is shown in Fig. 4 , when reversible and mechanism-based inhibition of hepatic CYP2C8 or CYP3A4 are the contributing mechanisms. Using bosutinib plasma-unbound peak and estimated unbound hepatic inlet peak concentrations of 0.021 and 0.23 mM, respectively (Daud et al., 2012) , the predicted maximal AUC increase was small for substrates completely metabolized by CYP2C8 (#1.2-fold). Also, Fig. 1 . Effects of protein kinase inhibitors on amodiaquine N-deethylation (CYP2C8 marker reaction) and midazolam 19-hydroxylation (CYP3A marker reaction) with or without a 30-min preincubation in the presence of NADPH in the screening. The inhibitors are ordered according to their time-dependent inhibitory effect. Erlotinib and gefitinib caused stimulation of midazolam 19-hydroxylation in direct inhibition experiments (also see Supplemental  Fig. 2) . The micromolar concentrations of the inhibitors are given. Incubations were conducted in HLM (0.1 mg/ml protein) with 2 mM substrate. Data points are mean + S.D. values of duplicate incubations. BOSU, bosutinib; BOSU iso, bosutinib isomer 1; CRIZ, crizotinib; DASA, dasatinib; ERLO, erlotinib; GEFI, gefitinib; LEST, lestaurtinib; NILO, nilotinib; PAZO, pazopanib; SARA, saracatinib; SORA, sorafenib; SUNI, sunitinib. The results of the whole screening are presented in Supplemental Fig. 2 . dmd.aspetjournals.org predictions based on direct CYP2C8 inhibition only (calculated using direct IC 50 values) by unbound peak concentrations of axitinib, gefitinib, lestaurtinib, and saracatinib resulted in minimal AUC increases (#1.1-fold; Supplemental Table 2 ).
For lestaurtinib, predictions based on its calculated plasmaunbound C max (0.28 mM) after doses of 80 mg twice daily (Supplemental Table 2 ) (http://aml17.cardiff.ac.uk/files/aml17_proto-colv2.pdf) yielded a predicted AUC increase of 2.7 for a substrate completely metabolized by hepatic CYP3A4. The corresponding increase after dosing of saracatinib 175 mg once daily (unbound C max of 0.082 mM) (Baselga et al., 2010 ) was predicted at 3.2. When using unbound hepatic inlet concentrations, lestaurtinib and saracatinib were predicted to cause maximal AUC increases of 2.8-and 5.5-fold, respectively. Furthermore, lestaurtinib and saracatinib were predicted to completely reduce (.99%) the activity of intestinal CYP3A4 at intestinal inhibitor concentrations of 9.8 and 4.3 mM, respectively (data not shown).
For midazolam, when considering inhibition of both intestinal and hepatic CYP3A4, the maximal AUC increase was predicted to 4.7-and 5.5-fold after coadministration with lestaurtinib and saracatinib, respectively, when unbound peak concentrations and the above doses of the inhibitors were used (Supplemental Table 2 ).
Predictions based on direct inhibition of hepatic CYP3A4 by axitinib and bosutinib and of CYP2C8 by gefitinib resulted in minor effects on the concentrations of a substrate completely metabolized by CYP3A or CYP2C8 (#1.1-fold AUC increase) (Supplemental Table 2 ). However, intestinal axitinib and bosutinib concentrations of 0.28 and 31 mM, respectively, were predicted to reduce the activity of intestinal CYP3A4 by 8 and 90% (data not shown).
Discussion
In the present study, 14 protein kinase inhibitors were initially screened for their potential time-dependent inhibitory effects on CYP2C8 and CYP3A activity. As compared with no preincubation, one inhibitor (bosutinib) exhibited increasing CYP2C8 inhibition and 11 inhibitors (bosutinib isomer 1, crizotinib, dasatinib, erlotinib, gefitinib, lestaurtinib, nilotinib, pazopanib, saracatinib, sorafenib, and sunitinib) caused increasing inhibition of CYP3A, following preincubation with NADPH. Eight of these inhibitors were recently reported to be time-dependent CYP3A inhibitors (Li et al., 2009; Li et al., 2010; Dong et al., 2011; Kenny et al., 2012; Mao et al., 2013) and were not further investigated. As novel findings, however, lestaurtinib and saracatinib were identified as irreversible mechanism-based inhibitors of CYP3A, and bosutinib as a weak irreversible mechanism-based inhibitor of CYP2C8. Consistent with criteria for mechanism-based inhibition (Silverman, 1995) , these conclusions are based on the following findings: the inhibitory effect on amodiaquine deethylation by bosutinib and on midazolam 19-hydroxylation by lestaurtinib and saracatinib were dependent on preincubation time, inhibitor concentration, and NADPH; the presence of a competitive inhibitor decreased the inhibition; and dialysis was unable to restore enzyme activity.
The obtained IC 50 value for direct CYP3A inhibition by lestaurtinib (4.7 mM) is in good agreement with previously reported K i values (4.3-5.2 mM) (http://issx.confex.com/issx/15na/webprogram/Paper11788. html, http://aml17.cardiff.ac.uk/files/aml17_protocolv2.pdf). However, preincubation with NADPH decreased the IC 50 2.2-fold, and in mechanism-based experiments the K I and k inact of lestaurtinib were determined to 31 mM and 0.040 1/min. Among the inhibitors tested, saracatinib caused the greatest, a 26-fold, reduction in IC 50 for CYP3A following preincubation, and its K I and k inact for CYP3A inhibition were 12.6 mM and 0.096 1/min. In our CYP2C8 experiments, bosutinib inhibited CYP2C8 with a direct IC 50 of 43 mM, and preincubation with NADPH reduced the IC 50 2.6-fold. Furthermore, the inhibition of CYP2C8 by bosutinib proceeded in a time-, concentration-, and NADPH-dependent manner, suggesting that it affects CYP2C8 by mechanism-based inhibition. Apparent K I and k inact values for CYP2C8 inactivation by bosutinib were estimated to 54.8 mM and 0.018 1/min. Our findings differ from those of a recent study, in which bosutinib did not exhibit time-dependent inhibitory effects on paclitaxel 6a-hydroxylation, another CYP2C8 marker reaction (Wang et al., 2014) . In addition, in this recent study, the inhibition of paclitaxel p-39-hydroxylation, which was used as a probe for CYP3A4 activity, increased following preincubation with NADPH as compared with no preincubation. As our results for CYP3A inhibition by bosutinib seem to be in reasonably good agreement with those of the manufacturer of bosutinib (no time-dependent inhibition, K i of 27 mM) (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1-s000ClinPharmR.pdf), possible explanations for this discrepancy could be differences in experimental conditions, for example, the substrate used and/or uncertainties concerning the inhibitor compound. The bosutinib isomer 1 was originally unintentionally sold to the research community (also to us) as authentic bosutinib by several vendors (http://www. pkcpharma.com/TwoOrMoreBosutinibs.html) (Levinson and Boxer, 2012; Beeharry et al., 2013; Braun and Schweizer, 2014) . The bosutinib results of the recent study correspond well with the inhibitory characteristics of bosutinib isomer 1 in our study. It should also be noted that this recent study observed weak mechanism-based inhibition of CYP3A4 by axitinib (Wang et al., 2014) . In our study, detailed timedependent inhibition studies were not carried out with axitinib, because preincubation reduced its IC 50 CYP3A inhibition by less than 1.5-fold, which is a common criterion for time-dependent inhibition studies (Grimm et al., 2009 ). Thus, our results are in line with previous literature (Supplemental Tables 3 and 4) .
When considering previous and present results, it seems that many kinase inhibitors affect P450 enzymes, in particular CYP3A, by mechanism-based inhibition. In this inhibition type, the inhibitor is first metabolized to a reactive intermediate, which inactivates the metabolizing enzyme by binding covalently to it (Silverman, 1995) . For instance, dasatinib is proposed to be bioactivated through hydroxylation and oxidation of its chloromethylphenyl ring, forming reactive quinone-imines and imine-methides, which may inactivate CYP3A4 (Li et al., 2009) . For imatinib, its piperazine and p-toluidine structures have been suggested to undergo hydroxylation and desaturation to imine and imine-methide intermediates, respectively . Quinone-iminies and imine-methides are reactive electrophiles, which, besides binding to P450 enzymes, may also The effect of the competitive CYP2C8 inhibitor montelukast on the preincubationdependent inactivation of CYP2C8 by bosutinib (150 mM) and that of the CYP3A inhibitor ketoconazole on the preincubation-dependent inactivation of CYP3A by lestaurtinib (30 mM) and saracatinib (10 mM)
Each experiment is compared with its own control, that is, either preincubation without kinase inhibitor or preincubation with competitive inhibitor but without kinase inhibitor. In the experiments, 30-min preincubations including human liver microsomes (HLM) (0.5 mg/ml) and NADPH were carried out with or without competitive inhibitor, in both the absence (controls) and presence of kinase inhibitor, followed by 20-fold dilution for measurement of residual CYP2C8 or CYP3A activity. Values are expressed as mean 6 S.D. of duplicates (controls were carried out as triplicates).
Variable
Percentage of Control Bosutinib alone 52.4 6 1.1 Bosutinib with montelukast (0.5 mM) 57.9 6 0.9 Bosutinib with montelukast (5 mM) 61.8 6 0.0 Lestaurtinib alone 48.5 6 4.6 Lestaurtinib with ketoconazole (0.1 mM) 53.2 6 3.3 Lestaurtinib with ketoconazole (1 mM) 60.4 6 1.1 Saracatinib alone 28.5 6 0.6 Saracatinib with ketoconazole (0.1 mM) 35.7 6 2.8 Saracatinib with ketoconazole (1 mM) 70.1 6 5. 6   TABLE 2 The effect of dialysis on the preincubation-dependent inactivation of CYP2C8 by bosutinib (150 mM) and of CYP3A by lestaurtinib (200 mM) and saracatinib (64 mM)
Each experiment is compared with its own control, that is, either preincubation without inhibitor or preincubation without inhibitor, followed by dialysis (3 ☓ 2 h at 4°C). In the experiments, human liver microsomes (HLM) (0.5 mg/ml) and NADPH were preincubated with or without inhibitor for 30 min. The samples were immediately dialyzed against sodium phosphate buffer three times for 2 h, followed by a 20-fold dilution and measurement of CYP2C8 or CYP3A4 activity. Values are expressed as mean 6 S.D. of duplicates or more. (Kalgutkar et al., 2007) . Both bosutinib and saracatinib contain a piperazine ring, which, following bioactivation, could be responsible for the inactivation of CYP2C8 and CYP3A observed in our study. Interestingly, whereas bosutinib exhibited timedependent inhibitory effect on CYP2C8 but not on CYP3A, bosutinib isomer 1 displayed opposite effects on these enzymes in the screening. However, as numerous structural elements have been suggested to cause mechanism-based inhibition (Kalgutkar et al., 2005) , more studies are needed to identify the bioactivation pathways of the mechanism-based inhibitors tested in the present study. Due to its irreversibility and time-and concentration-dependent nature, mechanism-based inhibition may result in slow-onset, cumulative, and long-lasting drug-drug interactions in vivo. In this study, we used static predictions considering both direct and mechanism-based inhibition to estimate the total drug-drug interaction risk of our in vitro findings. For bosutinib, interaction predictions based on unbound peak bosutinib concentrations resulted in insignificant AUC increases for CYP2C8 substrates. When considering inhibition of hepatic CYP3A4, unbound peak lestaurtinib and saracatinib concentrations were predicted to increase the AUC of a sensitive CYP3A4 substrate by up to 2.7-and 3.2-fold, respectively. In addition, intestinal concentrations of these inhibitors were estimated to completely inactivate CYP3A4 in the intestine (.99%). Thus, when intestinal CYP3A4 inhibition was included in the predictions, lestaurtinib and saracatinib were predicted to increase midazolam exposure by 4.7-and 5.5-fold, respectively. Using unbound hepatic inlet inhibitor concentrations, the interaction magnitudes were even higher (up to 8.4-fold). Thus, the predicted inhibition potency of lestaurtinib and saracatinib seems to be higher than that generally observed for kinase inhibitors, which affect CYP3A4 by mechanism-based inhibition (typically AUC increases of ,2-fold) (Supplemental Table 5 ) (Kenny et al., 2012) . However, some of these interaction studies have used a single inhibitor dose, which might have underestimated the maximal interaction magnitude, as the effect of mechanism-based inhibition can proceed with time and increasing inhibitor concentration. For instance, during multiple dosing, if the dosing frequency of inhibitor is higher than the synthesis rate of new enzyme, the result can be an accumulating enzyme inactivation with increasing time and doses. Lestaurtinib and saracatinib are currently in phase II/III (www.clinicaltrials.gov), and no official drug-drug interaction studies have been reported for these compounds yet.
Another possible consequence of mechanism-based inhibition is autoinhibition of the metabolism of the inhibitor itself. In our study, all inhibitors causing time-dependent CYP3A inhibition undergo metabolism by CYP3A4 (Supplemental Table 6 ). Therefore, it is possible that these inhibitors may inhibit their own CYP3A4-mediated metabolism during multiple dosing, so that other enzymes become more important than CYP3A4 with time. For instance, saracatinib exhibits nonlinear pharmacokinetics with a 3.8-fold accumulation at 50 mg once daily to 4.8-fold at 250 once daily (Baselga et al., 2010) , which might be partly due to inhibition of its own CYP3A4-mediated metabolism and accumulation of parent drug in hepatocytes. Thus, variability in CYP3A4 expression or activity together with mechanismbased CYP3A4 inhibition may partly explain the great variations observed in kinase inhibitor concentrations between patients. In addition, it highlights the potential importance of other enzymes in the metabolism of these kinase inhibitors.
Interestingly, as an additional finding and also observed in previous studies (Li et al., 2007; Dong et al., 2011; Kenny et al., 2012) , erlotinib and gefitinib stimulated midazolam 19-hydroxylation in our direct inhibition experiments. Sorafenib and sunitinib have also been reported to activate the formation of 19-hydroxymidazolam (Sugiyama et al., 2011; Kenny et al., 2012) , but this was not observed in our incubations. The heteroactivation mechanism for these kinase inhibitors has been reported to be substratedependent, as it has been observed with midazolam but not with the other CYP3A marker substrates nifedipine and testosterone (Li et al., 2007; Dong et al., 2011; Kenny et al., 2012) . It is not clear whether the activation by erlotinib and gefitinib occurs via CYP3A4 or CYP3A5, but for sorafenib and sunitinib it is reported to occur via CYP3A5 (Sugiyama et al., 2011) . In the present study, we did not differentiate between CYP3A4 and CYP3A5, but the lack of stimulation of midazolam 19-hydroxylation by sorafenib and sunitinib suggests that CYP3A4 activity was more prominent than that of CYP3A5 in the HLM batch used. The detailed mechanism and clinical relevance of the substrate-dependent heteroactivation by these inhibitors are currently unknown.
In conclusion, our study shows that bosutinib affects CYP2C8 by weak irreversible mechanism-based inhibition, and lestaurtinib and saracatinib are irreversible mechanism-based inhibitors of CYP3A. Furthermore, our findings support recent reports showing that crizotinib, dasatinib, erlotinib, gefitinib, nilotinib, pazopanib, sorafenib, and sunitinib are time-dependent CYP3A inhibitors. Thus, it appears that many members of this novel drug class contain structural elements, which are sensitive to bioactivation reactions forming reactive intermediates. Bioactivation may have consequences in terms of idiosyncratic drug reactions and drug-drug interactions, and it may ultimately also affect the pharmacokinetics of the inhibitor itself. Further studies are needed to elucidate why protein kinase inhibitors affect CYP enzymes by mechanism-based inhibition, and its clinical relevance. Fig. 4 . Prediction of the effect of bosutinib on the pharmacokinetics of CYP2C8 substrates, and that of lestaurtinib and saracatinib on the pharmacokinetics of CYP3A4 substrates in vivo (AUC po,i / AUC po ), assuming that intestinal bioavailability is unaffected. The figures illustrate how the effect of the kinase inhibitor on the AUC of the substrate depends on the concentration of inhibitor at the enzyme site and on the fraction of the substrate metabolized by CYP2C8 or CYP3A4 (fm P450 varying from 0.5 to 1.0). Predictions were carried out using the equation for both direct and mechanismbased inhibition. During treatment with 500 mg bosutinib daily, its average unbound peak concentration in plasma approximates to 0.021 mM (Daud et al., 2012) , and its unbound peak concentration at the hepatic inlet was estimated to 0.23 mM (indicated by the cyan-colored area). The corresponding concentrations for lestaurtinib after treatment with 80 mg twice daily were estimated to 0.28 and 0.28 mM (http://aml17.cardiff.ac.uk/files/aml17_protocolv2.pdf), respectively, and for saracatinib after treatment with 175 mg once daily to 0.082 and 0.16 mM (Baselga et al., 2010) , respectively. In addition, for saracatinib, the unbound steady state trough concentration of 0.040 mM is indicated by the border of the dark cyan area. 
